Dassault Systemes (DASTY), a French software company specializing in virtual twins of complex machines, has agreed to acquire ArisGlobal, a U.S.-based enterprise compliance platform serving the life sciences industry, for as much as $2 billion. Dassault will pay $1.8 billion in cash, with another $200 million linked to AI-related revenue milestones. The company is buying ArisGlobal from Nordic Capital, a Swedish private equity group that first invested in the business in 2019 and later increased its ownership. ArisGlobal serves more than 200 customers and uses artificial intelligence to support drug development, regulatory compliance, and safety monitoring. Dassault expects the acquisition to strengthen its ability to help life sciences companies manage clinical-trial evidence and meet regulatory standards.
The transaction represents Dassault's first major acquisition since the company removed its chairman in February following a steep decline in its share price. Dassault's shares had fallen about 26% this year through Wednesday's close as investors weighed concerns that emerging artificial intelligence tools could disrupt established software businesses. The company specializes in virtual twins, while developing AI world models may create new competitive pressure by helping systems understand and navigate the physical world. Earlier this year, Dassault was among the software companies affected by a broader global selloff in stocks viewed as vulnerable to AI disruption. Investors may therefore see the ArisGlobal acquisition as an attempt to expand Dassault's exposure to AI-enabled software while reinforcing its long-term position in life sciences.
Dassault also reported second-quarter revenue of 1.56 billion, representing a 2% increase from the previous year and exceeding the 1.54 billion average analyst estimate compiled by Bloomberg. However, the company's life sciences division continued to weigh on performance, with revenue declining 4% to 252 million in the second quarter after falling 12% year over year in the first quarter. Chief Executive Officer Pascal Daloz said in February that Dassault remained committed to life sciences as artificial intelligence reshapes the sector. The ArisGlobal transaction could help address weakness in that division by adding specialized capabilities in drug development, regulation, and safety monitoring, although the deal's full value will partly depend on whether ArisGlobal reaches the AI-related revenue milestones tied to the additional $200 million payment.